Minnesota-based Zyga Technologies closed a $10 million funding round with the help of 5 unnamed investors, according to regulatory filings.
The spinal devices maker raised the money through sales of equity and Series C-2 preferred stock, closing the round just 10 days after marking the 1st sale.
Zyga earlier this year closed enrollment in the GLISSADE study, a 40-patient clinical trial of its Glyder facet resurfacing system in treatment of chronic back pain. The device maker hopes to use the results of the study to win Investigational Device Exemption in the U.S. and CE Mark approval in the European Union.
